Short answer
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $75M (up 171.0% year over year) with net income of −$194M.
Q2 2026 key financials · XBRL
- Revenue
- $75M
- +171.0% YoY · +2.1% QoQ
- Net income
- −$194M
- −10.9% YoY · −46.4% QoQ
- Operating margin
- -226.0%
- EPS (diluted)
- −$1.37
- −1.5% YoY · −44.2% QoQ
Source: XBRL data from the ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Q2 2026 10-Q on SEC EDGAR. USD.
ARROWHEAD PHARMACEUTICALS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Outlook centered on plozasiran development, regulatory approval, commercialization, and potential future revenues
- Headwinds include clinical, regulatory, partnership, milestone, royalty, liquidity, and capital requirement uncertainties
Risk Factors
- No material changes to risk factors identified in the September 30, 2025 Form 10-K
- Carried-forward risks include business, operating-results, and financial-condition uncertainty
- No newly added regulatory, legal, compliance, operational, competitive, market, liquidity, debt, currency, or concentration risk disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARROWHEAD PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.